REG - RTW Biotech Opp. - Launch of Obesity Company Kailera Therapeutics

RTW Biotech OpportunitiesAnnouncement

03/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241003:nRSC7259Ga&default-theme=true

RNS Number : 7259G  RTW Biotech Opportunities Ltd  03 October 2024

LEI: 549300Q7EXQQH6KF7Z84

03 October 2024

RTW Biotech Opportunities Ltd

Launch of Obesity Company Kailera Therapeutics

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note the
announcement by new portfolio company, Kailera Therapeutics ("Kailera"), of
its launch and $400 million Series A financing round co-led by RTW Investments
(the "Investment Manager").

The Company, alongside other investment vehicles managed by RTW Investments,
co-led the Series A with Atlas Venture and Bain Capital Life Sciences, with
participation from Lyra Capital. The funding will be used to advance a
portfolio of next-generation therapies for obesity and related conditions.

 

Kailera's mission is to develop next-generation weight management therapies
that give people the power to transform their lives and elevate their overall
health. It is developing a broad, advanced, and differentiated portfolio of
clinical-stage injectable and oral therapies that have demonstrated potential
as best-in-class treatments for the treatment of chronic weight management.
Kailera's most advanced program, KAI-9531, is an injectable GLP-1/GIP receptor
dual agonist that demonstrated positive results in Phase 2 trials in obesity
and type 2 diabetes in China.

 

Roderick Wong, Managing Partner and CIO at the Investment Manager commented on
the launch, "We are immensely proud to co-lead the Series A launch of Kailera
Therapeutics, our fourth new company creation at RTW. Kailera represents a
significant step forward in addressing the huge market for chronic weight
management and metabolic diseases. With its clinically-validated pipeline and
experienced management team, we are confident that Kailera is well-positioned
to develop breakthrough therapies that will profoundly improve the lives of
patients worldwide. We look forward to supporting them on this transformative
journey."

 

The full text of the announcement can be accessed here
(https://www.globenewswire.com/news-release/2024/10/01/2955962/0/en/Kailera-Therapeutics-Launches-with-400-Million-Series-A-Financing-to-Advance-Portfolio-of-Next-Generation-Therapies-for-Obesity-and-Related-Conditions.html#:~:text=BOSTON%2C%20Oct.%2001%2C%202024,of%20obesity%20and%20related%20conditions.)
.

 

  For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107

 Charles Ryland

 Henry Wilson

 George Beale

 Deutsche Numis (Joint Corporate Broker)

                                                          +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000

 Edward Peel

 Alex Penney

 Cadarn Capital (Distribution & IR Partner)               +44 73 6888 3211

 David Harris

 Elysium Fund Management Limited                           +44 14 8170 3100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSLFMEELSEIS